13F HOLDINGS REPORT
Omega Fund Management, LLC
Quarter ended Q2 2024 · Filed August 14, 2024 · Accession 0000950123-24-008730
Total Value
$135.0M
Positions
11
Other Managers
0
Confidential Omitted
No
Holdings (11)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Nuvation Bio | NUVB | 13,275,884 | $38.8M | 28.72% |
| 2 | Lexeo Therapeutics | LXEO | 2,355,904 | $37.8M | 28.00% |
| 3 | Replimune Group | REPL | 2,461,319 | $22.2M | 16.41% |
| 4 | enGene Holdings Inc. | ENGNW | 1,076,357 | $10.2M | 7.52% |
| 5 | Alumis Inc | ALMS | 653,225 | $8.7M | 6.44% |
| 6 | Morphic Holding | 61775R105 | 159,846 | $5.4M | 4.03% |
| 7 | Sana Biotechnology, Inc. | SANA | 843,750 | $4.6M | 3.41% |
| 8 | Ikena Oncology | 45175G108 | 2,249,123 | $3.7M | 2.75% |
| 9 | Immunic Inc | IMUX | 1,788,160 | $2.0M | 1.47% |
| 10 | Syros Pharmaceuticals | 87184Q206 | 251,270 | $1.3M | 0.96% |
| 11 | enGene Holdings Inc. | ENGNW | 321,502 | $382,587 | 0.28% |